[Clinical-biological characteristics of infiltrating ductal carcinomas of the breast with estrogen receptor concentrations >300 fmol/mg protein].
Resino
C
C
Laboratorio de Biología Tumoral FJD. Departamento de Medicina Nuclear. Fundación Jiménez Díaz. Madrid.
Arias
J I
JI
Del Río
M C
MC
Sánchez Hermosa
C
C
Ruibal
A
A
D000782:Aneuploidy; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis; D004967:Estrogens; D005260:Female; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D009363:Neoplasm Proteins / Q000032:analysis*; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000473:pathology; D010455:Peptides / Q000032:analysis; D011374:Progesterone; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis
C113800:CD44v5 antigen; C112697:CD44v6 antigen; D004967:Estrogens; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins; D010455:Peptides; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C089984:tissue polypeptide specific antigen; D011374:Progesterone; D066246:ErbB Receptors; D010959:Tissue Plasminogen Activator